Sanofi slashes its Covid-19 timeline
Sanofi, the French drug company, has been more cautious than some of its rivals in projecting when its Covid-19 vaccines might be ready. Now, it’s announcing an acceleration of clinical trials to reach the market faster — and striking a $425 million deal to broaden its partnership with Translate Bio to develop one of them.
The company said its recombinant Covid-19 vaccine could be approved by the first half of 2021, six months earlier than it previously said, and that its new multiple sclerosis drug has entered clinical trials aimed at getting approval.
The company’s head of R&D, John Reed, cited the news as evidence that it is becoming bolder; he also said, in an interview, that the number of committees overseeing drug development have been cut from 33 to 3.
Reed presented new data on a molecule called IL-2, which he has studied for his whole career. It regulates how different types of blood cells behave. Last December, Sanofi spent $2.5 billion to purchase Synthorx, a company that was using artificial DNA base pairs not found in nature to alter IL-2 and produce a drug Reed said could be a “foundational asset” in cancer. The first human data, presented today, show that it produces types of white blood cells, known as natural killer and CD38 cells, known to fight cancer without boosting other parts of the immune system. Full data will be presented at a medical meeting later this year.
Read more.
The company said its recombinant Covid-19 vaccine could be approved by the first half of 2021, six months earlier than it previously said, and that its new multiple sclerosis drug has entered clinical trials aimed at getting approval.
The company’s head of R&D, John Reed, cited the news as evidence that it is becoming bolder; he also said, in an interview, that the number of committees overseeing drug development have been cut from 33 to 3.
Reed presented new data on a molecule called IL-2, which he has studied for his whole career. It regulates how different types of blood cells behave. Last December, Sanofi spent $2.5 billion to purchase Synthorx, a company that was using artificial DNA base pairs not found in nature to alter IL-2 and produce a drug Reed said could be a “foundational asset” in cancer. The first human data, presented today, show that it produces types of white blood cells, known as natural killer and CD38 cells, known to fight cancer without boosting other parts of the immune system. Full data will be presented at a medical meeting later this year.
Read more.
.png)
No hay comentarios:
Publicar un comentario